We recently published a list of While Wall Street Naps, These 10 Stocks Run Wild. In this article, we are going to take a ...

Roivant Sciences Ltd (ROIV) showcases robust cash reserves and strategic share repurchases while navigating legal uncertainties and competitive pressures.

Roivant Sciences Ltd. (($ROIV)) has held its Q4 earnings call. Read on for the main highlights of the call. Roivant Sciences Ltd. recently held ...

Roivant Sciences Ltd (NASDAQ:ROIV) is set to release its Q4 2025 earnings on May 29, 2025. The consensus estimate for Q4 2025 ...

Analysts anticipate Roivant Sciences to report an earnings per share (EPS) of $-0.16. The announcement from Roivant Sciences is eagerly anticipated, with investors seeking news of surpassing estimates ...

On Wednesday, H.C. Wainwright reaffirmed its Buy rating and $18.00 price target for Roivant Sciences (NASDAQ: ROIV), following a detailed discussion with the company’s CEO, Matthew Gline ...

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib ...

Roivant Sciences (NASDAQ:ROIV) shares are trading down by -40% across the past 12 months, and down 24% since the company joined the Nasdaq via a merger with the Special Purpose Acquisition Company ...

Roivant Sciences exhibits a strong financial outlook, backed by its substantial cash position, strategic acquisitions, and efficient R&D expense management. The company's innovative drug pipeline ...

Roivant Sciences' shares are up more than 42% over the past year. The company recently released a report on a phase 3 trial of its atopic dermatitis treatment. The company's other main therapy ...

Baker Bros. Advisors has been steadily buying Acadia Pharmaceuticals and Roivant Sciences this year. Both companies could be significantly undervalued right now. A top hedge fund has been steadily ...

Roivant Sciences (NASDAQ:ROIV) has observed the following analyst ratings within the last quarter: These 7 analysts have an average price target of $16.57 versus the current price of Roivant ...